Annex C
ESTIMATE OF ELIGIBLE PATIENTS (AS CALCULATED
BY ROCHE) RECEIVING HERCEPTIN PRE AND POST NICE GUIDANCE BY CANCER
NETWORK*
The Department of Health does not identify nor
calculate the percentage of eligible women receiving Herceptin.
The table below shows data provided by Roche (to the NAO), which
are calculated using their own algorithm. The Department can not
validate these data but have included them here, as they translate
to Figure 39 in the NAO's Report.
The Committee should note that the table below
is provided by the NAO and cannot be amended.
The figure for West London cancer network is
incorrect. The penetration (percentage of eligible cancer patients
receiving Herceptin 12-18 months after NICE approval) for West
London was 38%, not 4% . This makes the median 39% and improves
the West London ranking to 18th from 34th.
The NAO Report included an insert with a revised
Figure 39, in which West London was correctly ranked.
| 
